Shire Plc - Product Pipeline Review - 2016

Published: Mar, 2016 | Pages: 145 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Shire Plc - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Shire Plc - Product Pipeline Review - 2016', provides an overview of the Shire Plc's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Shire Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Shire Plc
- The report provides overview of Shire Plc including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Shire Plc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Shire Plc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Shire Plc's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Shire Plc
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Shire Plc's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 8
Shire Plc Snapshot 9
Shire Plc Overview 9
Key Information 9
Key Facts 9
Shire Plc - Research and Development Overview 10
Key Therapeutic Areas 10
Shire Plc - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Partnered Products 16
Partnered Products/Combination Treatment Modalities 17
Pipeline Products - Out-Licensed Products 18
Out-Licensed Products/Combination Treatment Modalities 19
Shire Plc - Pipeline Products Glance 20
Shire Plc - Late Stage Pipeline Products 20
Pre-Registration Products/Combination Treatment Modalities 20
Phase III Products/Combination Treatment Modalities 21
Shire Plc - Clinical Stage Pipeline Products 22
Phase II Products/Combination Treatment Modalities 22
Phase I Products/Combination Treatment Modalities 23
Shire Plc - Early Stage Pipeline Products 24
Preclinical Products/Combination Treatment Modalities 24
Shire Plc - Unknown Stage Pipeline Products 25
Unknown Products/Combination Treatment Modalities 25
Shire Plc - Drug Profiles 26
guanfacine hydrochloride ER 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
lifitegrast 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
parathyroid hormone 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
agalsidase alfa 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
budesonide 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
C1 esterase inhibitor (human) 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
icatibant acetate 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
lanadelumab 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lisdexamfetamine dimesylate 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
prucalopride succinate 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SHP-465 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
teduglutide (recombinant) 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
idursulfase 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
maribavir 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
mecasermin rinfabate (recombinant) 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
revexepride 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
SHP-610 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SHP-625 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
SHP-635 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SHP-640 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
VP-20621 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SHP-611 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SHP-622 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
SHP-623 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
SHP-627 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
volixibat potassium 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Drugs for Rare Diseases 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DX-2507 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
DX-4012 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Gene Therapy to Activate GTP Cyclohydrolase I for Parkinson's Disease 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
HTL-1071 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Monoclonal Antibodies for Genetic Diseases 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SC-435 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SHP-630 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SHP-637 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
SHP-639 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
SHP-641 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
etiguanfacine 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Shire Plc - Pipeline Analysis 83
Shire Plc - Pipeline Products by Target 83
Shire Plc - Pipeline Products by Route of Administration 85
Shire Plc - Pipeline Products by Molecule Type 86
Shire Plc - Pipeline Products by Mechanism of Action 87
Shire Plc - Recent Pipeline Updates 89
Shire Plc - Dormant Projects 126
Shire Plc - Discontinued Pipeline Products 128
Discontinued Pipeline Product Profiles 128
NRP-290 128
SPD-452 129
SPD-453 129
SPD-756 129
ALX-0646 129
BMN-185 129
C1 esterase inhibitor (human) 129
CX-516 129
ecallantide 130
HCV-796 130
HGT-1111 130
HGT-2610 130
icatibant acetate 130
isovaleramide 130
lisdexamfetamine dimesylate 130
mesalamine ER 131
metoclopramide hydrochloride 131
ramatercept 131
SHP-557 131
SHP-613 131
SHP-628 131
SPD-491 131
SPD-554 131
SPD-556 132
valrocemide 132
Shire Plc - Company Statement 133
Shire Plc - Locations And Subsidiaries 136
Head Office 136
Other Locations & Subsidiaries 136
Shire Plc - Key Manufacturing Facilities 143
Appendix 144
Methodology 144
Coverage 144
Secondary Research 144
Primary Research 144
Expert Panel Validation 144
Contact Us 144
Disclaimer 145

List of Tables

Shire Plc, Key Information 9
Shire Plc, Key Facts 9
Shire Plc - Pipeline by Indication, 2016 11
Shire Plc - Pipeline by Stage of Development, 2016 14
Shire Plc - Monotherapy Products in Pipeline, 2016 15
Shire Plc - Partnered Products in Pipeline, 2016 16
Shire Plc - Partnered Products/ Combination Treatment Modalities, 2016 17
Shire Plc - Out-Licensed Products in Pipeline, 2016 18
Shire Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016 19
Shire Plc - Pre-Registration, 2016 20
Shire Plc - Phase III, 2016 21
Shire Plc - Phase II, 2016 22
Shire Plc - Phase I, 2016 23
Shire Plc - Preclinical, 2016 24
Shire Plc - Unknown, 2016 25
Shire Plc - Pipeline by Target, 2016 83
Shire Plc - Pipeline by Route of Administration, 2016 85
Shire Plc - Pipeline by Molecule Type, 2016 86
Shire Plc - Pipeline Products by Mechanism of Action, 2016 87
Shire Plc - Recent Pipeline Updates, 2016 89
Shire Plc - Dormant Developmental Projects,2016 126
Shire Plc - Discontinued Pipeline Products, 2016 128
Shire Plc, Other Locations 136
Shire Plc, Subsidiaries 136
Shire Plc, Key Manufacturing Facilities 143